GT Biopharma (GTBP)
(Delayed Data from NSDQ)
$3.19 USD
-0.06 (-1.74%)
Updated May 14, 2024 02:58 PM ET
After-Market: $3.19 0.00 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for GT Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 14 | 21 | 58 | 7 | 16 |
Income After Depreciation & Amortization | -14 | -21 | -58 | -7 | -16 |
Non-Operating Income | 6 | 0 | 0 | -19 | -20 |
Interest Expense | 0 | 0 | 1 | 3 | 2 |
Pretax Income | -8 | -21 | -58 | -28 | -39 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -21 | -58 | -28 | -39 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -21 | -58 | -28 | -39 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -14 | -21 | -58 | -6 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -14 | -21 | -58 | -7 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.35 | 1.06 | 0.94 | 0.15 | 0.11 |
Diluted EPS Before Non-Recurring Items | -5.64 | -19.82 | -61.86 | -193.69 | -342.18 |
Diluted Net EPS (GAAP) | -5.64 | -19.82 | -61.86 | -193.69 | -342.18 |
Fiscal Year end for GT Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.17 | 3.12 | 3.63 | 3.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.17 | -3.12 | -3.63 | -3.67 |
Non-Operating Income | NA | 0.21 | 0.71 | 1.63 | 3.65 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.21 |
Pretax Income | NA | -2.96 | -2.42 | -1.99 | -0.23 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.96 | -2.42 | -1.99 | -0.23 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.96 | -2.42 | -1.99 | -0.23 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 1.37 | 1.34 | 1.30 |
Diluted EPS Before Non-Recurring Items | NA | NA | -1.80 | -2.70 | -2.40 |
Diluted Net EPS (GAAP) | NA | -2.04 | -1.80 | -1.50 | -0.30 |